Granite Investment Partners LLC Has $8.56 Million Stake in AbbVie Inc. $ABBV

Granite Investment Partners LLC lowered its holdings in AbbVie Inc. (NYSE:ABBV) by 21.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 36,989 shares of the company’s stock after selling 10,334 shares during the period. Granite Investment Partners LLC’s holdings in AbbVie were worth $8,564,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Kovitz Investment Group Partners LLC raised its position in shares of AbbVie by 8.3% in the third quarter. Kovitz Investment Group Partners LLC now owns 196,294 shares of the company’s stock valued at $45,450,000 after buying an additional 15,082 shares in the last quarter. Koshinski Asset Management Inc. increased its stake in AbbVie by 3.6% during the 3rd quarter. Koshinski Asset Management Inc. now owns 34,221 shares of the company’s stock worth $7,924,000 after acquiring an additional 1,193 shares during the period. Vestmark Advisory Solutions Inc. raised its holdings in AbbVie by 2.7% in the 3rd quarter. Vestmark Advisory Solutions Inc. now owns 44,232 shares of the company’s stock valued at $10,242,000 after acquiring an additional 1,175 shares in the last quarter. Channing Capital Management LLC raised its holdings in AbbVie by 10.5% in the 3rd quarter. Channing Capital Management LLC now owns 55,647 shares of the company’s stock valued at $12,885,000 after acquiring an additional 5,302 shares in the last quarter. Finally, Bleakley Financial Group LLC lifted its position in shares of AbbVie by 4.3% during the 3rd quarter. Bleakley Financial Group LLC now owns 70,047 shares of the company’s stock valued at $16,219,000 after acquiring an additional 2,897 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Trading Up 0.3%

ABBV opened at $224.94 on Monday. The company has a market cap of $397.56 billion, a P/E ratio of 95.31, a PEG ratio of 0.78 and a beta of 0.35. The company’s 50 day moving average is $224.04 and its 200-day moving average is $222.24. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The business had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same period in the prior year, the company earned $2.16 EPS. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Analysts Set New Price Targets

A number of brokerages recently commented on ABBV. The Goldman Sachs Group restated a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. UBS Group decreased their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Evercore dropped their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. JPMorgan Chase & Co. increased their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $252.79.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA approved the VENCLEXTA® (venetoclax) + acalabrutinib combination for previously untreated chronic lymphocytic leukemia (CLL). This is the first all‑oral, fixed‑duration combo for this setting, supported by Phase 3 AMPLIFY data—it can meaningfully expand uptake for Venclexta and acalabrutinib, strengthen AbbVie’s oncology franchise and offer a durable revenue stream versus one‑off treatments. U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
• Positive Sentiment: Industry write‑ups frame the FDA approval as a potential new standard for a slow‑growing blood cancer, highlighting better three‑year outcomes and the “time off therapy” selling point—this can accelerate physician adoption and market share vs. chemo regimens. FDA Approval For AbbVie/AstraZeneca’s Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
• Positive Sentiment: AbbVie opened a Phase 2a study for ABBV‑142 in idiopathic pulmonary fibrosis (IPF), broadening its respiratory/pulmonary pipeline beyond core immunology and oncology programs. Early‑stage pipeline depth helps investor sentiment around post‑Humira growth optionality. AbbVie Expands IPF Pipeline With New Phase 2a Study of ABBV-142
• Positive Sentiment: Board declared a $1.73 quarterly dividend (yield ~3.1%), reinforcing the income profile for dividend‑focused investors and supporting the stock’s defensive appeal. Dividend cadence and yield matter for total return expectations. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: Quarterly results and commentary show Rinvoq and Skyrizi continuing to drive top‑line growth and offset Humira erosion; that underpins management’s guidance but much of these dynamics are already reflected in recent estimates. Will Immunology Drugs Continue to Drive AbbVie’s Top Line in 2026?
• Neutral Sentiment: Coverage pieces ask whether AbbVie’s post‑Humira pipeline merits renewed investor attention — useful for narrative, but these are discussion pieces rather than new data that would immediately re‑rate the stock. Should AbbVie’s (ABBV) Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Neutral Sentiment: Marketing/PR items (new podcast, inclusion in dividend lists, media mentions) help brand and investor awareness but are unlikely to move fundamentals in the near term. AbbVie heads to ‘The Persistence Lab’ in new podcast highlighting healthcare innovation
• Negative Sentiment: Evercore noted Tremfya’s share gains but flagged possible limits to future earnings growth and trimmed its price target slightly—this is a modest analyst headwind that could cap upside if more firms follow with tepid updates. Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.